Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

1,040

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

January 31, 2006

Conditions
Alzheimer's DiseaseDementia, Alzheimer Type
Interventions
DRUG

rivastigmine transdermal patch

Trial Locations (75)

15601

Greensburg

30078

Snellville

33137

Miami

33154

Miami Beach

33321

Fort Lauderdale

33407

West Palm Beach

33486

Boca Raton

33952

Port Charlotte

37203

Nashville

43215

Columbus

45415

Dayton

63104

St Louis

68131

Omaha

73118

Oklahoma City

77030

Houston

78756

Austin

94109

San Francisco

98405

Tacoma

92868-3298

Orange

07740

Long Branch

08755

Toms River

08759

Whiting

Unknown

Santiago

Valparaíso

Brno

Brno-Bohunice

Hradec Králové

Olomouc

Prague

Copenhagen

Glostrup Municipality

Hillerød

Kuopio

Investigative Sites

Guatemala City

Beersheva

Haifa

Jerusalem

Petah Tikva

Tel Aviv

Lido di Camaiore

Milan

Pescara

Guadalajara Jalisco

Mexico City

Monterrey Nuevo Leon

Bodø

Oslo

Tromsø

Trondheim

Lima

Gdansk

Lublin

Poznan

Szczecin

Warsaw

Amadora

Coimbra

Moscow

Saint Petersburg

Bratislava

Michalovce

Jungbuk

KyungKi-province

Seoul

Gothenburg

Kalmar

Stockholm

Uppsala

Kaohsiung City

Taichung

Taipei

Taoyuan District

Ciudad Merida

00959

Bayamón

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY